Lv7
3780 积分 2022-09-02 加入
原发性免疫性血小板减少症患者应用TPO-RAs减停药的研究进展
1天前
已完结
Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000–2015)
1个月前
已完结
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
1个月前
已完结
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches
1个月前
已完结
Remibrutinib, a Novel Bruton Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency in Vitro
1个月前
已完结
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
1个月前
已完结
Remibrutinib in Chronic Spontaneous Urticaria
1个月前
已完结
Marginal zone lymphoma presenting with chylous ascites: A rare clinical manifestation and successful treatment with orelabrutinib–rituximab
1个月前
已完结
Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
1个月前
已完结
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study
1个月前
已完结
皖公网安备34019202002308
